New Research Identifies a Potential Target for Slowing Parkinson’s Progression

Scientists may have uncovered an important new pathway involved in the progression of Parkinson’s — one that could eventually lead to treatments designed not only to manage symptoms, but to slow the disease itself.

A recent study published in the journal Neuron examined the role of a protein called GPNMB, which researchers now believe may contribute to the spread of harmful alpha-synuclein proteins throughout the brain. Alpha-synuclein is considered one of the central drivers of Parkinson’s and is the primary component of Lewy bodies, the abnormal protein clumps found in the brains of people living with Parkinson’s.

For years, researchers have understood that Parkinson’s appears to spread progressively through different regions of the brain over time. However, the biological mechanisms behind that spread have remained unclear. This new research suggests that GPNMB — a protein involved in inflammation and immune activity — may help facilitate the uptake and movement of toxic alpha-synuclein between cells.

The study, conducted using laboratory models and human brain tissue, found that higher levels of GPNMB were associated with greater alpha-synuclein pathology. Researchers discovered that GPNMB appears to enhance the ability of brain cells to absorb fibrillar alpha-synuclein, the abnormal form of the protein associated with Parkinson’s progression. In simpler terms, GPNMB may act like an “accelerator” that helps harmful protein aggregates spread through the brain.

Importantly, scientists were also able to interrupt this process. Using antibodies designed to block GPNMB activity, researchers reduced the uptake of alpha-synuclein in laboratory experiments. The findings raise the possibility that therapies targeting GPNMB could someday help slow or even halt the spread of Parkinson’s-related neurodegeneration.

To further evaluate the relevance of their findings, researchers analyzed brain tissue from more than 1,600 individuals in the Penn Brain Bank. They found that people with genetic variants linked to increased GPNMB production also tended to show more extensive alpha-synuclein pathology. Notably, elevated GPNMB activity was not strongly associated with other neurodegenerative diseases such as Alzheimer’s disease, suggesting the pathway may be particularly important in Parkinson’s disease.

The findings build upon decades of research focused on alpha-synuclein and its role in Parkinson’s disease. Scientists have long known that abnormal accumulation and misfolding of alpha-synuclein contributes to the death of dopamine-producing neurons in the substantia nigra, the region of the brain most closely associated with Parkinson’s motor symptoms. More recent studies suggest that different “strains” or forms of alpha-synuclein may behave differently within the brain and may help explain variations in disease progression between individuals.

Researchers also increasingly believe inflammation plays a major role in Parkinson’s progression. Several recent studies have explored how immune responses, inflammatory proteins, and cellular stress may contribute to ongoing neurodegeneration. The new findings involving GPNMB fit into this broader understanding of Parkinson’s as a disease influenced not only by dopamine loss, but also by immune system dysfunction and abnormal protein handling within the brain.

While the research is still in early stages and far from becoming an approved treatment, experts say it represents an exciting development in the search for disease-modifying therapies. Current Parkinson’s medications primarily focus on managing symptoms such as tremor, rigidity, and slowed movement. No currently available treatment has definitively been shown to stop or reverse the progression of the disease itself.

That is why discoveries like this are generating growing interest within the Parkinson’s research community. By identifying the biological processes that allow harmful proteins to spread, scientists hope to eventually intervene earlier and protect vulnerable brain cells before irreversible damage occurs.

Researchers caution that additional studies and human clinical trials will be necessary before anti-GPNMB therapies can be considered safe or effective for people living with Parkinson’s disease. However, the findings represent another meaningful step toward understanding the complex biology of Parkinson’s — and toward the long-term goal of slowing disease progression and improving quality of life for millions worldwide.

In addition to its potential treatment implications, the study may also help advance efforts toward earlier diagnosis and personalized medicine in Parkinson’s. Researchers suggest that measuring GPNMB activity or related inflammatory markers could someday help identify individuals at higher risk for faster progression or more aggressive forms of Parkinson’s. This type of biomarker research is becoming an increasingly important focus within neurology, as scientists work to better understand why Parkinson’s symptoms and progression vary so significantly from person to person.